Published in Br J Exp Pathol on February 01, 1981
Mechanisms involved in mycobacterial growth inhibition by gamma interferon-activated bone marrow macrophages: role of reactive nitrogen intermediates. Infect Immun (1991) 3.54
Attempts to characterize the mechanisms involved in mycobacterial growth inhibition by gamma-interferon-activated bone marrow macrophages. Infect Immun (1988) 1.80
Hydrogen peroxide and superoxide release by alveolar macrophages from normal and BCG-vaccinated guinea-pigs after intravenous challenge with Mycobacterium tuberculosis. Br J Exp Pathol (1981) 1.39
Response of Mycobacterium tuberculosis to reactive oxygen and nitrogen intermediates. Mol Med (1996) 1.11
Direct activation of human monocyte-derived macrophages by a bacterial glycoprotein extract inhibits the intracellular multiplication of virulent Legionella pneumophila serogroup 1. Infect Immun (1987) 0.83
Mechanisms of acquired resistance in mouse typhoid. J Exp Med (1966) 9.20
Increased superoxide anion production by immunologically activated and chemically elicited macrophages. J Exp Med (1978) 6.50
Activation of macrophages in vivo and in vitro. Correlation between hydrogen peroxide release and killing of Trypanosoma cruzi. J Exp Med (1979) 5.22
Cellular hypersensitivity and cellular immunity in the pathogensis of tuberculosis: specificity, systemic and local nature, and associated macrophage enzymes. Bacteriol Rev (1968) 4.25
The 7H11 medium for the cultivation of mycobacteria. Am Rev Respir Dis (1968) 4.23
Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med (1979) 3.72
The virulence in the guinea-pig of tubercle bacilli isolated before treatment from South Indian patients with pulmonary tuberculosis. I. Homogeneity of the investigation and a critique of the virulence test. Bull World Health Organ (1961) 3.03
Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. J Gen Microbiol (1978) 2.58
VIRULENCE IN THE GUINEA-PIG, SUSCEPTIBILITY TO HYDROGEN PEROXIDE, AND CATALASE ACTIVITY OF ISONIAZID-SENSITIVE TUBERCLE BACILLI FROM SOUTH INDIAN AND BRITISH PATIENTS. J Pathol Bacteriol (1963) 2.21
New substrates for the fluorometric determination of oxidative enzymes. Anal Chem (1968) 1.43
The effects of some sulfhydryl compounds on growth of catalase-positive and catalase-negative tubercle bacilli. Am Rev Tuberc (1956) 1.35
Influence of infection with Toxoplasma on macrophage function, and role of macrophages in resistance to Toxoplasma. Am J Trop Med Hyg (1977) 1.15
The susceptibility of strains of Mycobacterium tuberculosis to catalase-mediated peroxidative killing. J Gen Microbiol (1980) 1.08
Oxidative metabolic responses of rabbit pulmonary alveolar macrophages. Blood (1979) 1.06
Host-parasite relationships in experimental airborne tuberculosis. VII. Fate of Mycobacterium tuberculosis in primary lung lesions and in primary lesion-free lung tissue infected as a result of bacillemia. J Infect Dis (1978) 1.00
Hydrogen peroxide release by rat alveolar macrophages: comparison with blood neutrophils. Infect Immun (1978) 0.84
The relationship between listericidal and mycobacteriostatic activity in BCG-vaccinated mice. J Reticuloendothel Soc (1974) 0.84
Effect of hyperoxia on superoxide anion and hydrogen peroxide production of polymorphonuclear leucocytes and alveolar macrophages. Br J Haematol (1977) 0.84
Mycobacterium tuberculosis strain H37Rv. J Med Lab Technol (1969) 0.82
Effect of phagocytosis on superoxide anion production and superoxide dismutase levels in BCG-activated and normal rabbit alveolar macrophages. J Reticuloendothel Soc (1978) 0.79
Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health Organ (1969) 12.55
A selective oleic acid albumin agar medium for tubercle bacilli. J Med Microbiol (1972) 6.78
Antigenic diversity of Mycobacterium tuberculosis and Mycobacterium bovis detected by means of monoclonal antibodies. Lancet (1981) 6.01
The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis (1980) 4.69
Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis (1999) 4.52
A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis (2008) 3.77
Vaccination against tuberculosis by DNA injection. Nat Med (1996) 3.76
IS6110 restriction fragment length polymorphism typing of clinical isolates of Mycobacterium tuberculosis from patients with pulmonary tuberculosis in Madras, south India. Tuber Lung Dis (1995) 3.76
The action of antituberculosis drugs in short-course chemotherapy. Tubercle (1985) 3.69
Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. Am Rev Respir Dis (1986) 3.46
Phagolysosome formation, cyclic adenosine 3':5'-monophosphate and the fate of Salmonella typhimurium within mouse peritoneal macrophages. J Gen Microbiol (1979) 3.18
Timing of relapse in short-course chemotherapy trials for tuberculosis. Int J Tuberc Lung Dis (2010) 3.07
Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis (1993) 3.01
Killing of Mycobacterium microti by immunologically activated macrophages. Nature (1981) 2.62
Sulphadimidine acetylation test for classification of patients as slow or rapid inactivators of isoniazid. Br Med J (1970) 2.61
Selective Kirchner medium in the culture of specimens other than sputum for mycobacteria. J Clin Pathol (1983) 2.61
Short-course chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis (1975) 2.59
Virulence and resistance to superoxide, low pH and hydrogen peroxide among strains of Mycobacterium tuberculosis. J Gen Microbiol (1978) 2.58
The use of murine monoclonal antibodies without purification of antigen in the serodiagnosis of tuberculosis. J Immunol Methods (1982) 2.57
Quality control in tuberculosis bacteriology. 1. Laboratory studies on isolated positive cultures and the efficiency of direct smear examination. Tubercle (1980) 2.57
Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med (1986) 2.35
Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ (1991) 2.32
Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis (1981) 2.31
Selective media in the isolation of tubercle bacilli from tissues. J Clin Pathol (1973) 2.17
The early bactericidal activity of rifabutin in patients with pulmonary tuberculosis measured by sputum viable counts: a new method of drug assessment. J Antimicrob Chemother (1993) 2.12
Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol (2000) 2.03
Basic mechanisms of chemotherapy. Chest (1979) 2.01
Controlled clinical trial of complete open surgical drainage and of prednisolone in treatment of tuberculous pericardial effusion in Transkei. Lancet (1988) 1.99
Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide. Antimicrob Agents Chemother (1996) 1.97
Application of DNA fingerprinting with IS986 to sequential mycobacterial isolates obtained from pulmonary tuberculosis patients in Hong Kong before, during and after short-course chemotherapy. Tuber Lung Dis (1993) 1.94
A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother (2000) 1.90
A computer-assisted bacteriology reporting and information system. J Clin Pathol (1978) 1.86
The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.76
[Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy]. Bull Int Union Tuberc (1978) 1.75
Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Final report at 5 years: prognostic value of various measures. Int J Tuberc Lung Dis (2002) 1.73
An effective method of RNA extraction from bacteria refractory to disruption, including mycobacteria. Nucleic Acids Res (1997) 1.69
Primary drug resistance in pulmonary tuberculosis in Great Britain: second national survey, 1963. Tubercle (1966) 1.65
Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infect Immun (1998) 1.64
Airway responsiveness in low birthweight children and their mothers. Arch Dis Child (1988) 1.58
Phagosome-lysosome fusion and cyclic adenosine 3':5'-monophosphate in macrophages infected with Mycobacterium microti, Mycobacterium bovis BCG or Mycobacterium lepraemurium. J Gen Microbiol (1979) 1.57
Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages. Am Rev Respir Dis (1992) 1.56
The correlation of bacteriophage types of Mycobacterium tuberculosis with guinea-pig virulence and in vitro-indicators of virulence. J Gen Microbiol (1978) 1.55
Mycobacterium microti may protect itself from intracellular destruction by releasing cyclic AMP into phagosomes. Nature (1975) 1.52
Strains of Mycobacterium tuberculosis differ in susceptibility to reactive nitrogen intermediates in vitro. Infect Immun (1994) 1.51
Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. J Clin Microbiol (2000) 1.51
Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis. Am Rev Respir Dis (1977) 1.50
Immunodiagnostic assays for tuberculosis and leprosy. Br Med Bull (1988) 1.49
Protein synthesis is shutdown in dormant Mycobacterium tuberculosis and is reversed by oxygen or heat shock. FEMS Microbiol Lett (1998) 1.48
Bactericidal action of ofloxacin, sulbactam-ampicillin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (1996) 1.48
Bioavailability of rifampin in experimental murine tuberculosis. Antimicrob Agents Chemother (1992) 1.48
Protection against tuberculosis by passive transfer with T-cell clones recognizing mycobacterial heat-shock protein 65. Immunology (1994) 1.46
Suitability of rifampicin for intermittent administration in the treatment of tuberculosis. Tubercle (1970) 1.45
Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong. Int J Tuberc Lung Dis (1997) 1.44
Suitability of isoniazid and ethambutol for intermittent administration in the treatment of tuberculosis. Tubercle (1968) 1.43
Observations in vitro on the suitability of pyrazinamide for intermittent chemotherapy of tuberculosis. Tubercle (1970) 1.41
Drug resistance in mycobacteria. Br Med Bull (1984) 1.40
A single mycobacterial protein (hsp 65) expressed by a transgenic antigen-presenting cell vaccinates mice against tuberculosis. Immunology (1994) 1.39
Rifabutin in the treatment of newly diagnosed pulmonary tuberculosis. Tuber Lung Dis (1995) 1.39
Hydrogen peroxide and superoxide release by alveolar macrophages from normal and BCG-vaccinated guinea-pigs after intravenous challenge with Mycobacterium tuberculosis. Br J Exp Pathol (1981) 1.39
Culture of specimens other than sputum for Mycobacteria. J Clin Pathol (1974) 1.39
HLA typing in the Hong Kong Chest Service/British Medical Research Council study of factors associated with the breakdown to active tuberculosis of inactive pulmonary lesions. Am Rev Respir Dis (1988) 1.38
Quality control in tuberculosis bacteriology. 2. The origin of isolated positive cultures from the sputum of patients in four studies of short course chemotherapy in Africa. Tubercle (1980) 1.36
Macrophage antimycobacterial mechanisms. Br Med Bull (1988) 1.36
In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle (1987) 1.35
Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S Afr Med J (1996) 1.34
The bacterial DNA content of mouse organs in the Cornell model of dormant tuberculosis. Tuber Lung Dis (1995) 1.33
Secretion of a macrophage-activating factor distinct from interferon-gamma by human T cell clones. Eur J Immunol (1984) 1.33
Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke. Am J Cardiol (1988) 1.31
In vitro observations on the suitability of new rifamycins for the intermittent chemotherapy of tuberculosis. Tubercle (1987) 1.30
Laboratory aspects of intermittent drug therapy. Postgrad Med J (1971) 1.28
Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. Int J Tuberc Lung Dis (1998) 1.28
The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med (1997) 1.27
Amikacin in the treatment of pulmonary tuberculosis. Tubercle (1983) 1.23
Examination of sputum by smear and culture in case-finding. Bull Int Union Tuberc (1968) 1.23
Geographic distribution of bacteriophage types of Mycobacterium tuberculosis. Am Rev Respir Dis (1969) 1.23
The effect of gamma-interferon during Mycobacterium bovis (BCG) infection in athymic and euthymic mice. Microb Pathog (1986) 1.22
Bactericidal action of gatifloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob Agents Chemother (2005) 1.21
Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis (2006) 1.20
Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report. Am J Respir Crit Care Med (1998) 1.20
Characterization of T cells that confer a high degree of protective immunity against tuberculosis in mice after vaccination with tumor cells expressing mycobacterial hsp65. Infect Immun (1996) 1.20
In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis. Tubercle (1987) 1.19
Division and death rates of Salmonella typhimurium inside macrophages: use of penicillin as a probe. J Gen Microbiol (1979) 1.19